Consolidated statement of profit or loss and other comprehensive income
for the year ended 30 September 2020
Currently viewing: Consolidated statement of profit or loss and other comprehensive income / Next: Consolidated statement of financial position
for the year ended 30 September 2020
| Notes | 2020 R'm |
2019 R'm |
|||||
| Revenue | 2 | 25 386 | 25 672 | ||||
|---|---|---|---|---|---|---|---|
| Other income | 2 | 208 | 232 | ||||
| Drugs and consumables | (5 497) | (5 311) | |||||
| Employee benefits expense | 3 | (9 534) | (8 860) | ||||
| Retirement benefit asset and post-employment medical aid income | 32 | 39 | |||||
| Depreciation on property, plant and equipment | (1 594) | (1 236) | |||||
| Amortisation of intangible assets | (604) | (586) | |||||
| Repairs and maintenance expenditure on property, plant and equipment | (688) | (540) | |||||
| Occupational expenses | (879) | (971) | |||||
| Hospital service expenses | (828) | (838) | |||||
| Communication expenses | (388) | (365) | |||||
| Radiology service costs | (1 405) | (1 376) | |||||
| Professional, legal and secretarial fees | (499) | (582) | |||||
| Provision for expected credit losses | (186) | (19) | |||||
| Other expenses | 6 | (1 344) | (1 315) | ||||
| Operating profit¹ | 2 180 | 3 944 | |||||
| Fair value adjustments to contingent consideration | (37) | 2 | |||||
| Fair value loss on derivative financial instruments | 4 | (5) | (438) | ||||
| Gain on derecognition of lease asset and liability | 75 | – | |||||
| Impairment of assets and investments | 11 | (798) | (164) | ||||
| Profit on disposal of investment in joint venture | – | 1 501 | |||||
| Profit on disposal of investment in subsidiary | – | 11 | |||||
| Loss on disposal of property, plant and equipment | (6) | – | |||||
| Transaction costs relating to acquisitions and disposals | (17) | (148) | |||||
| Other | – | (22) | |||||
| Finance income | 5 | 93 | 60 | ||||
| Finance cost¹ | 5 | (918) | (1 058) | ||||
| Share of associates’ and joint ventures’ net profit after tax | 12 | 14 | 18 | ||||
| Profit before tax¹ | 6 | 581 | 3 706 | ||||
| Tax expense | 7 | (543) | (835) | ||||
| Profit after tax | 38 | 2 871 | |||||
| Other comprehensive income/(loss), net of tax | |||||||
| Items that may be reclassified to profit or loss | |||||||
| Movement in foreign currency translation reserve (FCTR) | 1 833 | 117 | |||||
| Items that may not be reclassified to profit or loss | |||||||
| Retirement benefit asset and post-employment medical aid | (13) | (54) | |||||
| Total comprehensive income for the year | 1 858 | 2 934 | |||||
| Profit after tax attributable to: | |||||||
| Ordinary equity holders of the parent | (93) | 2 569 | |||||
| Non-controlling interest | 131 | 302 | |||||
| 38 | 2 871 | ||||||
| Total comprehensive income attributable to: | |||||||
| Ordinary equity holders of the parent | 1 708 | 2 622 | |||||
| Non-controlling interest | 150 | 312 | |||||
| 1 858 | 2 934 | ||||||
| (Loss)/earnings per share (cents) | 8 | (6.4) | 176.4 | ||||
| Diluted loss/(earnings) per share (cents) | 8 | (6.4) | 175.8 | ||||
| 1 | Impact of adopting IFRS 16 on statement of profit or loss – refer to Annexure A – 1.15. |
The accompanying notes are an integral part of these consolidated financial statements.